Every 10-Q that NeuroOne Medical Technologies Corporation (NMTC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NMTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NMTC filings page.
NeuroOne Medical Technologies Corporation reports continued operating losses and tight liquidity for the quarter and nine months ended June 30, 2026. Product revenue was $1.97 million for the quarter and $6.73 million for the nine months, modestly above the prior-year periods, but license revenue of $3.0 million recognized in 2025 did not recur.
The company posted a quarterly net loss of $2.01 million and a nine‑month net loss of $5.83 million, significantly larger than the prior‑year nine‑month loss of $1.99 million. Operating cash outflows rose to $5.53 million for the nine months, reducing cash and cash equivalents to $2.05 million and total assets to $6.19 million. Accumulated deficit reached $84.4 million.
Management discloses substantial doubt about the ability to continue as a going concern, estimating current cash plus post‑quarter ATM proceeds will fund operations only into January 2027. The business remains highly concentrated, with one customer contributing essentially all product revenue, and relies on equity financing, including an at‑the‑market program and a March 2026 private placement. A 1‑for‑6 reverse stock split was completed in April 2026 to address Nasdaq listing requirements.
NeuroOne Medical Technologies Corporation restated its March 31, 2026 quarter after discovering duplicated product revenue and cost entries on modified customer purchase orders. The correction reduced product revenue by $529,135 and gross profit by $296,353 for the three and six months ended March 31, 2026, and lowered total assets and stockholders’ equity by $296,353. The company reported a six‑month net loss of $3.8 million and ended March 31, 2026 with $2.8 million in cash and cash equivalents. Management states the errors were not due to intentional misconduct and is implementing stronger purchase order controls. The filing also reiterates substantial doubt about NeuroOne’s ability to continue as a going concern, noting cumulative losses of about $82.4 million and projecting that current cash, planned revenue from its Zimmer distribution agreement, and cost reductions will fund operations only through September 2026.
NeuroOne Medical Technologies reported higher product revenue but continued losses and a going concern warning. For the quarter ended March 31, 2026, product revenue was $2.39 million, up from $1.39 million a year earlier, with six‑month product revenue of $5.28 million.
The company posted a quarterly net loss of $2.09 million and a six‑month net loss of $3.52 million, widening from $0.49 million in the prior‑year period. Cash and cash equivalents were $2.8 million, after $4.44 million of operating cash outflows in six months.
Management states there is substantial doubt about NeuroOne’s ability to continue as a going concern beyond its current runway, which it believes extends through September 2026, absent additional capital. A 1‑for‑6 reverse stock split became effective in April 2026, and a March 2026 private placement raised $670,400. Revenue remains highly concentrated in a single customer under the Zimmer distribution relationship.
NeuroOne Medical Technologies reported a net loss of $1.4 million for the quarter ended December 31, 2025, after earning $1.8 million in the prior-year period, mainly because last year included $3.0 million of one-time license revenue from its Zimmer agreement. Product revenue from its cleared neuromodulation devices was $2.9 million, down modestly from $3.3 million, and product gross margin slipped to 54.2% from 58.9% due to pricing mix and higher costs.
Cash and cash equivalents were $3.6 million at December 31, 2025, versus $6.6 million at September 30, 2025, as operating activities used $3.1 million of cash in the quarter. Management believes existing cash, expected Zimmer-related product revenues and planned expense reductions can fund operations through September 2026, but still states that substantial doubt exists about the company’s ability to continue as a going concern. NeuroOne remains highly dependent on a single major customer for product revenue and on third-party manufacturers, and it has received a Nasdaq notice for not meeting the minimum bid price requirement, with an extension to regain compliance by May 4, 2026.
NeuroOne Medical Technologies reported growing product sales and improved liquidity for the period ended June 30, 2025. Product revenue increased to $1.70 million in the quarter and $6.36 million year-to-date, while the Company also recognized $3.0 million of license revenue from an amended distribution agreement with Zimmer, which was recorded in the nine months ended June 30, 2025. Total assets were $10.82 million and cash and cash equivalents rose to $8.04 million, up from $1.46 million at September 30, 2024, largely reflecting an April 2025 equity financing that generated approximately $8.24 million of net proceeds.
Despite revenue gains, NeuroOne reported a net loss of $1.50 million for the quarter and $1.99 million for the nine months, with an accumulated deficit of $76.99 million. The Company reduced its warrant liability from $2.14 million to $1.04 million, and notes continued concentration risk with one customer accounting for the majority of product sales. Management states available cash plus anticipated Zimmer-related revenue and planned expense reductions should fund operations for at least twelve months, but additional financing may be required thereafter.